In this selection, we summarize for you the most important scientific news of 2020 in the field of structural heart disease. 01- Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations<a href="https://solaci.org/en/2020/12/17/the-most-read-articles-in-structural-heart-disease-of-2020/" title="Read more" >...</a>
A normal or (on the other end) a very high level of NT-proBNP should make us look for a cause other than aortic stenosis. If aortic stenosis is not the culprit of the clinical case, a transcatheter aortic valve replacement (TAVR) will hardly benefit these patients. These data come from a recently published paper in<a href="https://solaci.org/en/2020/12/11/nt-probnp-level-predicts-who-may-benefit-from-tavr/" title="Read more" >...</a>
Mechanically-expanding valve Lotus Edge was discontinued worldwide, as recently informed by its manufacturer, Boston Scientific. This is a voluntary recall of all Lotus valve inventory, and the immediate suspension of the program. The United States Food and Drug Administration (FDA) approved Lotus Edge in 2019 for patients with severe aortic stenosis and high surgical risk.<a href="https://solaci.org/en/2020/12/03/boston-scientific-discontinues-lotus-valve-and-makes-a-new-bet/" title="Read more" >...</a>
01- How To De-Escalate Prasugrel After Acute Coronary Syndrome? Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. Read more HERE 02- Not All Coronary Spasms Are the Same: Benefits of Acetylcholine Patients with documented spasm<a href="https://solaci.org/en/2020/11/17/the-most-read-scientific-articles-in-interventional-cardiology-2/" title="Read more" >...</a>
Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under conscious sedation. Conscious sedation has been adopted in clinical practice as a natural way of simplifying and conducting the procedure in the least invasive way possible. Currently, up to 50% of patients undergo TAVR under conscious sedation, but<a href="https://solaci.org/en/2020/10/28/conscious-versus-general-anesthesia-in-tavr/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) results durable at 5 years to treat failed surgical bioprosthetic valves and at one year to treat valves percutaneously. Regardless the type of the failed valve, the solution is TAVR. The 5 year follow up of the PARTNER 2 valve-in-valve (ViV) showed that TAVR as treatment for failed surgical bioprosthetic<a href="https://solaci.org/en/2020/10/21/tct-2020-tavr-appears-to-be-the-solution-for-all-dysfunctional-biological-valves/" title="Read more" >...</a>
One-year outcomes of the head to head trial between CoreValve Evolut R vs Sapien 3 showed a significantly higher difference in stroke vs. patients receiving the self-expanding valve (Sapien 3 6.9% vs Evolut R 1%; p=0.002). The SOLVE-TAVI randomized 2×2 patients with severe aortic stenosis and high surgical risk to Sapien 3 or Evolut R and<a href="https://solaci.org/en/2020/10/21/tct-2020-surprising-differences-in-stroke-between-sapien-3-and-evolut-r/" title="Read more" >...</a>
The consequences of deferring transcatheter aortic valve replacement (TAVR) procedures because of the COVID 19 pandemic are piling up. Untreated severe aortic stenosis patients who had been scheduled for TAVR are seeing increased risk of all events, even mortality. According to recent studies published in JAMA, deferring TAVR in patients with symptomatic aortic stenosis is<a href="https://solaci.org/en/2020/10/08/death-stroke-and-hospitalization-while-waiting-for-tavr/" title="Read more" >...</a>
We never saw it coming, such a pleiotropic effect: who would have though a mechanical device could have such a systemic anti-inflammatory effect? Transcatheter aortic valve replacement (TAVR) does in fact have it. The shear stress aortic stenosis produces activates multiple inflammatory responses mediated by monocytes. This study identified the most important mechanoreceptor, involved in<a href="https://solaci.org/en/2020/09/28/tavr-as-anti-inflammatory-an-effect-few-imagined/" title="Read more" >...</a>
In patients with large and extra-large annuli, transcatheter aortic valve replacement (TAVR) is safe and feasible with 3rd generation valves: the 29mm balloon expandable valve Sapien-3, and their competitor, the self-expandable 34mm Evolut R. The largest size of both devices was designed specifically for patients with large or extra-large annuli. However, one of them seems<a href="https://solaci.org/en/2020/09/01/3rd-generation-valves-in-large-and-x-large-annuli/" title="Read more" >...</a>